E-Mail
Researchers from the University of Oxford and their partners have today reported findings from a Phase IIb trial of a candidate malaria vaccine, R21/Matrix-M, which demonstrated high-level efficacy of 77% over 12-months of follow-up. In their findings (posted on SSRN/Preprints with
The Lancet) they note that they are the first to meet the World Health Organization s Malaria Vaccine Technology Roadmap goal of a vaccine with at least 75% efficacy.
The authors report (in findings in press with
The Lancet) from a Phase IIb randomised, controlled, double-blind trial conducted at the Clinical Research Unit of Nanoro (CRUN) / Institut de Recherche en Sciences de la Santé (IRSS), Burkina Faso. 450 participants, aged 5-17 months, were recruited from the catchment area of Nanoro, covering 24 villages and an approximate population of 65,000 people.
By Yucatan Times on December 21, 2020
Share
The intense heat of the state would complicate the situation of bringing some vaccines that need certain temperatures.
MERIDA Yucatán (Times Media Mexico) – The arrival of the vaccine against Covid-19 is perhaps the most anticipated event of 2020. With more than 72 million cases diagnosed on the planet and more than 1.6 million deaths, the pandemic has focused the pharmaceutical industry’s activity on searching for a “cure.”
At the same time, world leaders, scientists, and the World Health Organization (WHO) call for the “antidote” to be accessible and safe for all. Large laboratories are applying for emergency licenses to make them available to the public as soon as possible.